This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Oxaliplatin

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

This is a diaminocyclohexane platinum compound which forms crosslinks in DNA, so inhibiting DNA replication.

Treatment with Oxaliplatin is associated with a 10% probability of an objective response when given alone or in combination with 5-fluorouracil and leucovirin in patients who have already received 5-fluoruracil (1).

NICE recommend the use of oxaliplatin in combination with 5-fluorouracil and folinic acid as an option for the adjuvant treatment of patients with stage III (Dukes? C) (2)

Possible adverse effects include:

  • mild paraesthesia/dysaesthesia, generally triggered by cold, occurs in most patients after oxaliplatin infusion and may last a few days
  • rarely acute dyspnoea and dysphagia may occur following oxaliplatin infusion - these symptoms generally resolve within a few hours without treatment (3)
  • 10-20% of patients develop longer-lasting, severe sensory symptoms secondary to sensory peripheral neuropathy and related to the cumulative dose of oxaliplatin - generally these symptoms resolve after stopping treatment - however associated functional impairment may last for 3-4 months
  • diarrhoea is a common adverse effect and may be severe
  • neutropenia may occur

The summary of product characteristics should be consulted before prescribing this drug.

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.